Chemokine receptors expression on T cells and response to HAART among chronic HIV-1-infected subjects

Current HIV Research

Volumn 6, Issue 6, 2008, Pages 539-543

  Brito, Adriana ^a   Rigato, Paula O ^a   Almeida, Alexandre ^a   Fernandes, Simone S ^a   Gonsalez, Cláudio R ^a   Fonseca, Luiz A M ^a   Duarte, Alberto J S ^a   Casseb, Jorge ^a,b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b Sao Paulo University ^*  (Brazil)

Author keywords

Antiretoviral therapy; CCR5; Chemokines; Co receptors; CXCR4; HIV 1

Indexed keywords

ANTIRETROVIRUS AGENT; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; STROMAL CELL DERIVED FACTOR 1; CXCR4 PROTEIN, HUMAN; UNCLASSIFIED DRUG;

ADULT; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHRONIC DISEASE; DOWN REGULATION; DRUG RESPONSE; FEMALE; GENE EXPRESSION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; REVIEW; VIRUS LOAD; ARTICLE; BIOSYNTHESIS; COMPARATIVE STUDY; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; ISOLATION AND PURIFICATION; MIDDLE AGED; T LYMPHOCYTE; VIREMIA; VIROLOGY;

ADULT; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; RECEPTORS, CCR5; RECEPTORS, CXCR4; T-LYMPHOCYTES; VIREMIA;

EID: 58149252400     PISSN: 1570162X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157016208786501436     Document Type: Review

References (20)

1. Mueller A, Strange PG. The chemokine receptor, CCR5. Int J Biochem Cell Biol 2004; 36: 35-8.
2. Rot A, von Andrian UH. Chemokines in innate and adaptive host defense: basic chemokines grammar for immune cells. Annu Rev Immunol 2004; 22: 891-928.
3. Oppermann M. Chemokine receptor CCR5: insights into structure, function, and regulation. Cell Signal 2004; 16: 1201-10.
4. + T cells. Science 1995; 270: 1811-5.
5. Kuhmann SE, Hartley O. Targeting chemokine receptors in HIV: a status report. Annu Rev Pharmacol Toxicol 2008; 48: 425-61.
6. + T cells are associated with asymptomatic HIV-1 infection. Proc Natl Acad Sci USA 2000; 97: 13812-7.
7. Liu R, Paxton WA, Choe S, et al. Homozygous defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 1996; 86: 367-77.
8. Paxton WA, Kang S. Chemokine receptor allelic polymorphisms: relationships to HIV resistance and disease progression. Semin Immunol 1998; 10: 187-94.
9. Tsimanis A, Kalinkovich A, Bentwich Z. Soluble chemokine CCR5 receptor is present in human plasma. Immunol Lett 2005; 96: 55-61.
10. Lee B, Sharron M, Montaner LJ, et al. Quantification of CD4, CCR5 and CXCR4 levels on lymphocyte subsets dendritic cells and differentially conditioned monocyte-derived macrophages. Proc Natl Acad Sci USA 1999; 96: 5215-20.
11. Balter, M. Chemokine mutation slows progression. Science 1998; 279: 327.
12. Winkler C, Modi W, Smith MW, et al. Genetic restriction of AIDS pathogenesis by an SDF-1 chemokine gene variant. ALIVE Study, Hemophilia Growth and Development Study (HGDS), Multicenter AIDS Cohort Study (MACS), Multicenter Hemophilia Cohort Study (MHCS), San Francisco City Cohort (SFCC). Science 1998; 279: 389-93.
13. Reiche EM, Bonametti AM, Voltarelli JC, Morimoto HK, Watanabe MA. Genetic polymorphisms in the chemokine and chemokine receptors: impact on clinical course and therapy of the human immunodeficiency virus type 1 infection (HIV-1). Curr Med Chem 2007; 14: 1325-34.
14. Brito A, Almeida A, Gonsalez CR, et al. Successful HAART is associated with high B-chemokines levels in chronic HIV-1-infected patients. AIDS Res Hum Retroviruses 2007; 23: 906-12.
15. Giovannetti A, Ensoli F, Mazzetta F, et al. CCR5 and CXCR4 chemokine receptor expression and β-chemokine prodution during early T cell repopulation induced by higly active anti-retroviral therapy. Clin Exp Immunol 1999; 118: 87-97.
16. Nicholson JK, Browning SW, Hengel RL, et al. CCR5 and CXCR4 expression on memory and naive T cells in HIV-1 infection and response to highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2001; 27: 105-15.
17. Ensoli F, Fiorelli V, Alario C, et al. Decreased T cell apoptosis and T cell recovery during highly active antiretroviral therapy (HAART). Clin Immunol 2000; 97: 9-20.
18. + T-cell activation. Antivir Ther 2007; 12: 971-5.
19. Westby M, Lewis M, Whitcomb J. Emergence of CXCR4-using human immunodeficiency virus type 1 (HIV-1) variants in a minority of HIV-1-infected patients following treatment with the CCR5 antagonist maraviroc is from a pretreatment CXCR4-using virus reservoir. J Virol 2006; 80: 4909-20.
20. Fätkenheuer G, Pozniak AL, Johnson MA, et al. Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1. Nat Med 2005; 11: 1170-2.